Bmy And Pfe Report Phase 3 Results, Stock Update On Mygn And Eqlb
PROTEONOMIX, INC
PROTEONOMIX, INC. (OTCBB:PROT), announced that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the PROT investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. ("XGen"), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.
Myriad Genetics, Inc. (Nasdaq:MYGN) announced that Peter D. Meldrum, President and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 9:45 a.m. Eastern on September 14, 2010, at the Grand Hyatt Hotel in New York City and the Stifel Nicolaus Healthcare Conference, at 10:20 a.m. Eastern on September 15, 2010, at the Four Seasons Hotel in Boston.
The presentations will be available to interested parties through a live audio webcast accessible through a link on the investor relations section of Myriad's Web site at www.myriad.com.
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer (NYSE:PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the Hot Line session on August 31, 2010, in Stockholm, Sweden.
Atrial fibrillation (AF) is the most common serious chronic arrhythmia, affecting about 4.5 million people in Europe and 2.2 million people in the United States.1 Patients with AF are at five times greater risk for stroke compared with the general population.2 Fifteen percent of all strokes are attributable to AF, and one quarter of all strokes in persons older than 80 years are attributable to AF.1
In 2007, PFE and BMY entered into a worldwide collaboration to develop and commercialize apixaban, an investigational oral anticoagulant discovered by BMY. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizers global scale and expertise in this field.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received fifteen thousand dollars in cash from a third party (EEA, Inc ) for (7) days of advertising for EQ Labs, Inc. (EQLB.PK)
by: Bill Pennyman
Coordinating Your Moving and Junk Removal Stock Update On Wvvi, Stz, Eqlb From Pennytobuck.com Settle Down And Enjoy At These Glorious Cities At Greece For Your Once In A Lifetime Land Of The God Settle Down And Relish At The Pleasing Villages At Meteora For Your Best Land Of The Gods Visits Nfl Tickets - Dmb And Taylor Swift To Be Part Of 2010 Kickoff IPO: How Public Company Stock is Created Feel Quiet And Indulge In At The Glorious Hideaways In Halkidiki For Your Perfect Land Of The Gods V ACID ATTACKS AND THEIR CONSEQUENCES Stem And Prot On Pennytobuck.com's Stock Watchlist Stock Update On Gg,nsu, Orfg From Pennytobuck.com Stock Highlight On Taxs, Cs, Etfc From Pennytobuck.com Be Calm And Have Fun At The Glorious Cities At Eastern Aegean For Your Most Wonderful Greece Breaks Loosen Up And Luxuriate In At These Delightful Places In Olympia For Your Once In A Lifetime Land Of